Table 3.

Best corrected visual acuity (BCVA), central macular thickness (CMT), frequency of uveitic macular edema (UME) and number of ocular relapses recorded between the time of the switch and the last follow-up assessment distinguishing patients according to the different follow-up duration.

Follow-up duration	BCVA at the switch	BCVA at last assessment	p-value	CMT at the switch	CMT at last assessment	p-value	UME at the switch	UME at last assessment	p-value	Number of ocular flares after the switch
3 months (n = 20)	10 ± 1.95	9 ± 2.1	0.109	275.9 ± 43.1	283 ± 37.7	0.859	2	0	0.468	0
6 months (n = 6)	6.6 ± 3.5	6.8 ± 3.4	0.317	280 ± 15	278.7 ± 14.5	0.414	1	0	> 0.99	0
12 months (n = 11)	7.3 ± 2.5	8.4 ± 2.7	0.014	294.4 ± 37.4	273.9 ± 28.5	0.056	6	2	0.184	14

“n” refers to the number of patients.